ACXP Acurx Pharmaceuticals
- 2.250
- +0.090+4.17%
- 2.300
- +0.050+2.22%
Acurx Pharmaceuticals News
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | DEFA14A: Others
Acurx Pharmaceuticals | DEF 14A: Definitive information statements
Acurx Pharmaceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Acurx Pharmaceuticals | 8-K: Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Acurx Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Acurx Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | 8-K: Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | 8-K: Current report
Acurx Pharmaceuticals | DEFA14A: Others
Acurx Pharmaceuticals | DEF 14A: Definitive proxy statements
Acurx Pharmaceuticals | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Acurx Pharmaceuticals | 8-K: Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Acurx Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Analysis
Price Target
No Data
